What changes should be made now to the U.S. healthcare system to make it better when things return to a new normal, and, in the event of future pandemics.
The so-called “rebate rule” was reported dead in 2019. Here’s why that may not be entirely true.
Two years after launch, biosimilars for rheumatoid arthritis and other lifelong conditions captured little market share.
Schaeffer Center research indicates public investment into biomedical innovation yields substantial economic and social return in California.
Our analysis shows the measure resulted in over 56,000 jobs created and added approximately $10 billion to the state’s economy.
In a study published in Pharmacoeconomics, we find multiple blockbuster drugs have received exclusivity of more than 10 years through the Orphan Drug Act, thereby delaying access to generic/biosimilar equivalents.
Blood tests that find malignancies before they spread couldtransform our approach to treatment, Goldman wrote in Scientific American.
Electronic health records — which doctors and hospitals have been collecting for a decade — could powerfully and precisely guide the pandemic response.
Stuck at home, people are consulting doctors over the internet rather than in person—an approach to healthcare with many lasting benefits.
The speed and extent of biosimilar penetration differ across provider types. Provider awareness and incentives are significantly associated with biosimilar uptake.